ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0036

The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects

Carlos Pérez-Sánchez1, Luz Marina Sanchez-Mendoza2, Nuria Barbarroja3, M.Carmen Abalos-Aguilera4, Maria Luque-Tevar5, Alejandra Patiño-Trives5, Iván Arias de la Rosa3, Cristobal Román-Rodriguez6, Juan Antonio Moreno2, Maria Isabel Buron2, Jose Antonio Gonzalez-Reyes2, Marta Rojas-Gimenez4, Eduardo Collantes-Estevez6, alejandro Escudero6, Jose Manuel Villalba2 and Chary lopez-pedrera6, 1IMIBIC, Córdoba, Spain, 2Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, 3University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 4Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Córdoba, Cordoba, Spain, 5Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, 6IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain

Meeting: ACR Convergence 2021

Keywords: antiinflammatory, antioxidant, leukocytes, NAD+ booster, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: RA – Etiology & Pathogenesis Poster (0011–0045)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: NAD+ is a key cofactor and second messenger for multiple cellular processes that exhibits antioxidant, anti-apoptotic, and anti-inflammatory properties. Numerous publications and clinical trials have shown the beneficial effects of NAD+ boosters in different diseases. However, to date no studies have evaluated the NAD+ metabolism and the therapeutic effects of NAD+ boosters in RA patients.
Aims: 1- To study the NAD+ metabolism in RA patients and its association with key clinical features; 2-To evaluate the effect of anti-TNF therapy in the NAD+ metabolism; 3- To analyze the beneficial effects of NAD+ boosters in leukocytes from active RA patients.

Methods: Plasma and PBMCs were purified from 100 RA patients and 50 healthy donors (HDs). NAD+ levels were determined by using the NAD/NADH-Glo Assay. Gene expression analysis of markers related to the synthesis (NAMPT, NMNAT2, NRK1), transport (Cx43) and consumption of NAD+ (PARP-1, Sirtuin-1, CD157, CD38 y CD73) were performed in PBMCs by RT-PCR.

Moreover, in a second cohort of 50 RA patients treated with anti-TNF therapy, changes in the levels of NAD+ were analyzed before and after 6 months of treatment.

In parallel, PBMCs from a third cohort of 10 active RA patients were treated ex vivo with 1 mM of NAD+ boosters including nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). After 24 hours, intracellular reactive oxygen species (ROS) levels and the % of apoptotic PBMCs were assessed by flow cytometry. Finally, a panel of key pro-inflammatory genes was evaluated by RT-PCR.

Results: NAD+ levels were significantly reduced in plasma of RA patients compared with HDs, and directly related to disease activity. Accordingly, the expression levels of genes involved in the consumption of NAD+ such as SIRT-1, CD38 and PARP-1 were found up-regulated in PBMCs from RA patients. The levels of NAMPT and Cx43 were found increased suggesting a compensatory response of the organism against the depletion of NAD+ levels. The altered metabolism of NAD+ was associated with the increased expression of several cytokines such as TNF, IL6, IL1, IL8 and CCL2 highlighting the role of inflammation in the altered NAD+ metabolism.

Anti-TNF therapy restored the altered NAD+ levels towards those showed by HDs. Furthermore, the clinical response promoted by anti-TNF therapy correlated with changes in NAD+ levels.

In vitro treatments of PBMCs isolated from active RA patients with NAD+ boosters significantly increased the NAD+ levels and promoted a deep reduction of intracellular ROS levels, the percentage of apoptotic cells and the expression levels of key inflammatory mediators, such as IL-6, IL-8, IL-1b, TNF-α, CCL2, IL-23, and STAT-3.

Conclusion: 1. NAD+ metabolism is altered and associated with the disease activity and the pro-inflammatory status of RA patients. 2. Anti-TNF therapy restored NAD+ levels, which was directly linked to the clinical effectiveness. 3. NAD+ boosters reduced the oxidative, apoptotic, and inflammatory profile of RA leukocytes through the parallel increase of intracellular NAD+ levels. Thus, NAD+ boosters might be considered novel therapeutic tools for RA patients.

Supported by: FIS18/0837,RTI2018-100695-B-I00,P18-RT-4264,CVI276


Disclosures: C. Pérez-Sánchez, None; L. Sanchez-Mendoza, None; N. Barbarroja, None; M. Abalos-Aguilera, None; M. Luque-Tevar, None; A. Patiño-Trives, None; I. Arias de la Rosa, None; C. Román-Rodriguez, None; J. Moreno, None; M. Buron, None; J. Gonzalez-Reyes, None; M. Rojas-Gimenez, None; E. Collantes-Estevez, None; a. Escudero, None; J. Villalba, None; C. lopez-pedrera, None.

To cite this abstract in AMA style:

Pérez-Sánchez C, Sanchez-Mendoza L, Barbarroja N, Abalos-Aguilera M, Luque-Tevar M, Patiño-Trives A, Arias de la Rosa I, Román-Rodriguez C, Moreno J, Buron M, Gonzalez-Reyes J, Rojas-Gimenez M, Collantes-Estevez E, Escudero a, Villalba J, lopez-pedrera C. The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-nad-metabolism-is-altered-in-rheumatoid-arthritis-and-its-modulation-with-nad-boosters-exhibits-key-anti-inflammatory-and-anti-oxidant-effects/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-nad-metabolism-is-altered-in-rheumatoid-arthritis-and-its-modulation-with-nad-boosters-exhibits-key-anti-inflammatory-and-anti-oxidant-effects/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences